SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Amendment No. 1)

(Rule 13d-102)

Under the Securities Exchange Act of 1934

NLS Pharmaceutics Ltd.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

H57830103

(CUSIP Number)

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐	Rule 13d-1(b)
☐	Rule 13d-1(c)
☒	Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. H57830103 13G Page 2 of 5 Pages

1.	Names of Reporting Persons Eric Konofal
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (See Instructions) (a) ☐ (b) ☐
3.	SEC Use Only
4.	Citizenship or Place of Organization Switzerland

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	Sole Voting Power 1,025,000
	6.	Shared Voting Power 0
	7.	Sole Dispositive Power 1,025,000
	8.	Shared Dispositive Power 0

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,025,000
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
11.	Percent of Class Represented by Amount in Row (9) 3.2% (1)
12.	Type of Reporting Person (See Instructions) IN

(1) The ownership percentage reported is based on 32,428,893 shares of Common Stock outstanding as reported in the Issuer’s Form F-3, filed with the U.S. Securities and Exchange Commission on January 13, 2023.

CUSIP No. H57830103 13G Page 3 of 5 Pages

Item 1(a).	Name of Issuer:
	NLS Pharmaceutics Ltd.
Item 1(b).	Address of Issuer’s Principal Executive Offices:
	The Circle 6 8058 Zurich, Switzerland
Item 2(a).	Name of Person Filing:
	This Statement is filed on behalf of Eric Konofal.
Item 2(b).	Address of Principal Offices or, if None, Residence:
	The address of the Reporting Person is:
	c/o NLS Pharmaceutics Ltd. The Circle 6 8058 Zurich, Switzerland
Item 2(c).	Citizenship:
	Eric Konofal is a citizen of Switzerland.
Item 2(d).	Title of Class of Securities:
	Common Shares
Item 2(e).	CUSIP Number:
	H57830103
Item 3.	If the Statement is being filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the filing person is a:
	Not applicable.

(a)	☐	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	☐	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	☐	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	☐	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	☐	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)	☐	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)	☐	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)	☐	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	☐	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
(j)	☐	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
(k)	☐	Group, in accordance with §240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:_________________________

CUSIP No. H57830103 13G Page 4 of 5 Pages

Item 4. Ownership.

(a)	Amount beneficially owned:
	1,025,000 common shares
(b)	Percent of class:
	3.2% (1)
(c)	Number of shares as to which such person has:
(i)	Sole power to vote or direct the vote: 1,025,000 Common Shares
(ii)	Shared power to vote or direct the vote: 0
(iii)	Sole power to dispose or to direct the disposition of: 1,025,000  Common Shares
(iv)	Shared power to dispose or to direct the disposition of: 0

Item 5.	Ownership of Five Percent or Less of a Class.
	If this statement is being filed to report the fact that as of the date hereof the reporting person had ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.
Item 6.	Ownership of More than Five Percent on Behalf of Another Person.
	Not applicable.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not applicable.
Item 8.	Identification and Classification of Members of the Group.
	Not applicable.
Item 9.	Notice of Dissolution of Group.
	Not applicable.
Item 10.	Certification.
	Not applicable.

(1) The ownership percentage reported is based on 32,428,893 shares of Common Stock outstanding as reported in the Issuer’s Form F-3, filed with the U.S. Securities and Exchange Commission on January 13, 2023.

CUSIP No. H57830103 13G Page 5 of 5 Pages

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 13, 2023

(Date)

/s/ Eric Konofal

(Signature)

Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).